Sargramostim

沙莫司亭

Report date: 2026/04/08 15:42:17

Base Information

Drug NameSargramostim
Drug Alias NameSargramostimum沙格司亭Sagramostim沙拉莫司亭Interberin +[20] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionGranulocyte-macrophage colony-stimulating factor receptor stimulantsGranulocytes stimulantsHaematopoiesis stimulants +[5] 
TargetsGranulocyte-macrophage colony-stimulating factor receptor
Therapy Area/IndicationsUveal melanomaRejection of renal transplantationCoronavirus Disease 2019 (COVID-19) +[53] 
Global Approved IndicationsAcute Radiation SyndromeNeutropeniaPulmonary Alveolar Proteinosis
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1991/03/05
Country/TerritoryBulgariaCanadaUnited States +[18] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesPartner Therapeutics IncDana-Farber Cancer InstituteNational Center For Advancing Translational Sciences +[11] 
Inactive CompaniesSandozUniversity Of California San FranciscoLisata Therapeutics Inc +[22] 
Active IndicationsCoronavirus Disease 2019 (COVID-19)Acute Radiation SyndromeNeutropenia +[13] 
Inactive IndicationsUveal melanomaRejection of renal transplantationSkin Melanoma +[40] 

Other Information

ATC CodeL03AA09
Related LinksWikipediaDrugBankKEGG